论文部分内容阅读
目的比较替吉奥联合多西他赛及希罗达联合多西他赛治疗转移性乳腺癌的临床疗效。方法将2007年1月-2009年我院88例转移性乳腺癌患者随机分成两组各44例,治疗组应用替吉奥联合多西他赛进行治疗,对照组应用希罗达联合多西他赛进行治疗,比较两组患者临床总有效率、无进展生存期及不良反应发生率。结果观察组总有效率、平均无进展生存期均高于对照组(P<0.01),两组不良反应发生率无明显差异(P>0.05)。结论替吉奥联合多西他赛治疗转移性乳腺癌临床疗效确切,不良反应可耐受,值得临床推荐。
Objective To compare the clinical efficacy of tegaserod in combination with docetaxel and xeloda in combination with docetaxel in the treatment of metastatic breast cancer. Methods From January 2007 to 2009, 88 patients with metastatic breast cancer in our hospital were randomly divided into two groups of 44 patients. The treatment group was treated with Tegaserod combined with docetaxel. The control group was treated with Xeloda combined with docetaxel Race for treatment, compared the two groups of patients with total clinical efficiency, progression-free survival and adverse reactions. Results The total effective rate and average progression-free survival rate in the observation group were significantly higher than those in the control group (P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination of tiotropium and docetaxel is effective in the treatment of metastatic breast cancer. The adverse reactions are tolerable and should be clinically recommended.